Is switching to T-DM1 still justified in HER2-negative residual breast cancer after neoadjuvant systemic therapy?

Category Primary study
JournalBreast
Year 2025
This article has no abstract
Epistemonikos ID: b4cd642a8692b52403310e01a832bbd42170bcd6
First added on: Feb 14, 2025